<?xml version='1.0' encoding='utf-8'?>
<document id="26536846"><sentence text="Strong Specific Inhibition of UDP-glucuronosyltransferase 2B7 by Atractylenolide I and III." /><sentence text="Drug-metabolizing enzymes inhibition-based drug-drug interaction remains to be the key limiting factor for the research and development of efficient herbal components to become clinical drugs" /><sentence text=" The present study aims to determine the inhibition of uridine 5'-diphospho-glucuronosyltransferases (UGTs) isoforms by two important efficient herbal ingredients isolated from Atractylodes macrocephala Koidz, atractylenolide I and III" /><sentence text=" In vitro recombinant UGTs-catalysed glucuronidation of 4-methylumbelliferone was used to determine the inhibition capability and kinetics of atractylenolide I and III towards UGT2B7, and in silico docking method was employed to explain the possible mechanism"><entity charOffset="56-77" id="DDI-PubMed.26536846.s4.e0" text="4-methylumbelliferone" /></sentence><sentence text=" Atractylenolide I and III exhibited specific inhibition towards UGT2B7, with negligible influence towards other UGT isoforms"><entity charOffset="1-18" id="DDI-PubMed.26536846.s5.e0" text="Atractylenolide I" /></sentence><sentence text=" Atractylenolide I exerted stronger inhibition potential than atractylenolide III towards UGT2B7, which is attributed to the different hydrogen bonds and hydrophobic interactions"><entity charOffset="1-18" id="DDI-PubMed.26536846.s6.e0" text="Atractylenolide I" /><entity charOffset="135-143" id="DDI-PubMed.26536846.s6.e1" text="hydrogen" /><pair ddi="false" e1="DDI-PubMed.26536846.s6.e0" e2="DDI-PubMed.26536846.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26536846.s6.e0" e2="DDI-PubMed.26536846.s6.e1" /></sentence><sentence text=" Inhibition kinetic analysis was performed for the inhibition of atractylenolide I towards UGT2B7" /><sentence text=" Inhibition kinetic determination showed that atractylenolide I competitively inhibited UGT2B7, and inhibition kinetic parameter (Ki) was calculated to be 6" /><sentence text="4 μM" /><sentence text=" In combination of the maximum plasma concentration of atractylenolide I after oral administration of 50 mg/kg atractylenolide I, the area under the plasma concentration-time curve ration AUCi /AUC was calculated to be 1"><entity charOffset="55-70" id="DDI-PubMed.26536846.s10.e0" text="atractylenolide" /><entity charOffset="111-128" id="DDI-PubMed.26536846.s10.e1" text="atractylenolide I" /><pair ddi="false" e1="DDI-PubMed.26536846.s10.e0" e2="DDI-PubMed.26536846.s10.e0" /><pair ddi="false" e1="DDI-PubMed.26536846.s10.e0" e2="DDI-PubMed.26536846.s10.e1" /></sentence><sentence text="17, indicating the highly possible drug-drug interaction between atractylenolide I and drugs mainly undergoing UGT2B7-catalysed metabolism" /><sentence text="" /></document>